お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合， 注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。 但し、日本語版が必要な場合は、受注後8～10営業日となります。 お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

本報告書は、ゲノムベースの医薬品の世界市場、容量、生産量、収益、価格の概要を紹介します。2019~2023年の歴史的な市場収益/売上データ、2024年の予想、および2030年までのCAGRの予測を含む世界市場動向の分析。本レポートはメーカー、地域、製品の種類と端末業界の角度から世界と主要地域の市場現状と将来性を研究した、このレポートでは、世界と主要地域のトップメーカーを分析し、製品タイプとアプリケーション/端末業界別にゲノムベースの医薬品市場を分類しています。
本レポートでは世界のゲノムベースの医薬品市場の主な参加者として、企業概要、販売数量、収益、価格、粗利益率、ポートフォリオ、地理的位置、重要な発展を次のパラメータに基づいて紹介します。本研究に含まれる主な企業は：Sandoz International、Teva pharmaceutical industries、Mylan、3SBio、Shanghai Fosun Pharmaceutical、Tonghua Dongbao Pharmaceutical、Biocon、Reliance Life Sciences、Probiomed、Biosidus、AMEGA Biotech、Celltrion、LG Life Science、Dong-A Pharmaceutical

レポートはゲノムベースの医薬品の主要生産者を調査し、主要地域や国の消費状況も提供します。ゲノムベースの医薬品の今後の市場の可能性のハイライト、およびこの市場をさまざまなセグメントおよびサブセグメントに予測するための主要な地域/国の焦点。アメリカとカナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、およびその他の国の国別データと市場価値分析。

2019年から2030年までのタイプ別および用途別、売上高、収益、価格別のセグメントデータを分析します。
タイプ別市場セグメント：
    Insulin
    Growth Hormone
    Monoclonal Antibody
    Other

用途別の市場セグメント：
    Hospital
    Pharmaceutical Factory
    Other

本レポートの詳細内容
本レポートは、世界のゲノムベースの医薬品市場の現状と将来展望を包括的に分析し、グローバルの主要地域における開発動向の綿密な調査を通じて、読者に包括的な市場分析を提示するものであります。市場の全体像を把握するために、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてゲノムベースの医薬品市場を細分化しています。この分類と応用により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2019年から2024年まで、そして2030年までの予測として、メーカー別、地域別（地域レベル、国レベル）のゲノムベースの医薬品生産量、成長率、市場シェアを調査している。

二. 消費面では、ゲノムベースの医薬品の売上高を地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2019年から2024年まで、2030年までの予測。

三.主要メーカーのゲノムベースの医薬品売上高、収益、市場シェア、業界ランキング、2019年から2024年までのデータに焦点を当てています。世界のゲノムベースの医薬品市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づいて競争状況と市場ポジショニングの分析。

四.本ゲノムベースの医薬品のレポートでは関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立てるのに役立つ洞察を提供することを目的としています。 売上高、成長動向、生産技術、用途、エンドユーザー産業の市場規模に関する詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。

章の概要
第1章：ゲノムベースの医薬品のレポート範囲、各市場セグメントの市場規模、将来の開発可能性などを含む、さまざまな市場セグメントのエグゼクティブサマリー（タイプ別およびアプリケーション別など）を紹介します。市場の現状と、短期から中期、および長期的な進化の可能性を高度に見ることができます。（2019～2030）
第2章： ゲノムベースの医薬品の世界と主要生産者（地域／国）の生産／アウトプット。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています。（2019～2030）
第3章：世界、地域、国レベルにおけるゲノムベースの医薬品の売上（消費）、収益。各地域とその主要国の市場規模と発展の可能性を定量的に分析し、世界の各国の市場発展、将来の発展の見通し、市場空間を紹介します。（2019～2030）
第4章ゲノムベースの医薬品メーカーの競争状況、価格、売上高、収益、市場シェアと業界ランキング、最新の開発計画、合併、買収情報などの詳細分析。（2019～2024）
第5章：ゲノムベースの医薬品の各市場セグメントの売上高、収益、平均価格、および開発可能性をカバーした種類別のさまざまな市場セグメントの分析を提供し、読者がさまざまな市場セグメントでブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第6章：アプリケーション別の様々な市場セグメントの分析を提供し、各市場セグメントの売上高、収益、平均価格、発展の可能性をカバーし、読者が異なる下流市場でのブルーオーシャン市場を見つけるのに役立ちます。（2019～2030）
第7章：北米（米国・カナダ）：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第8章：ヨーロッパ：タイプ別、用途別、国別、セグメント別の売上高と収益。（2019～2030）
第9章：中国：タイプ別、アプリケーション別、セグメント別の売上高、収益。（2019～2030）
第10章：アジア（中国を除く）：タイプ別、用途別、地域別、セグメント別の売上高、収益。（2019～2030）
第11章：中東、アフリカ、中南米：タイプ別、用途別、国別、セグメント別の売上高、収益。（2019～2030）
第12章：ゲノムベースの医薬品の主要メーカーの概要を提供し、製品の説明と仕様、ゲノムベースの医薬品の売上高、収益、価格、粗利益率、最近の発展など、市場の主要企業の基本的な状況を詳細に紹介します。（2019～2024）
第13章：産業チェーン、販売チャネル、主要原材料、販売代理店および顧客の分析。
第14章：ゲノムベースの医薬品の市場動態、市場の最新の動向、市場の推進要因と制約要因、業界内のメーカーが直面する課題とリスク、業界内の関連政策の分析を紹介します。
第15章：レポートの要点と結論。

The global Genome-Based Drug market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Covers:
This report presents an overview of global market for Genome-Based Drug, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.
This report researches the key producers of Genome-Based Drug, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Genome-Based Drug, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Genome-Based Drug sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Genome-Based Drug market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Genome-Based Drug sales, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sandoz International, Teva pharmaceutical industries, Mylan, 3SBio, Shanghai Fosun Pharmaceutical, Tonghua Dongbao Pharmaceutical, Biocon, Reliance Life Sciences and Probiomed, etc.

Market Segmentation
By Company
    Sandoz International
    Teva pharmaceutical industries
    Mylan
    3SBio
    Shanghai Fosun Pharmaceutical
    Tonghua Dongbao Pharmaceutical
    Biocon
    Reliance Life Sciences
    Probiomed
    Biosidus
    AMEGA Biotech
    Celltrion
    LG Life Science
    Dong-A Pharmaceutical

Segment by Type
    Insulin
    Growth Hormone
    Monoclonal Antibody
    Other

Segment by Application
    Hospital
    Pharmaceutical Factory
    Other

Segment by Region
    US & Canada
        U.S.
        Canada
    China
    Asia (excluding China)
        Japan
        South Korea
        China Taiwan
       Southeast Asia
        India
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
    Latin America, Middle East & Africa
        Brazil
        Mexico
        Turkey
        Israel
        GCC Countries

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Genome-Based Drug in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Genome-Based Drug manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Genome-Based Drug sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

List of Tables
    Table 1. Global Genome-Based Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Table 2. Major Manufacturers of Insulin
    Table 3. Major Manufacturers of Growth Hormone
    Table 4. Major Manufacturers of Monoclonal Antibody
    Table 5. Major Manufacturers of Other
    Table 6. Global Genome-Based Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Table 7. Global Genome-Based Drug Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 8. Global Genome-Based Drug Revenue by Region (2019-2024) & (US$ Million)
    Table 9. Global Genome-Based Drug Revenue by Region (2025-2030) & (US$ Million)
    Table 10. Global Genome-Based Drug Revenue Market Share by Region (2019-2024)
    Table 11. Global Genome-Based Drug Revenue Market Share by Region (2025-2030)
    Table 12. Global Genome-Based Drug Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 13. Global Genome-Based Drug Sales by Region (2019-2024) & (Kiloton)
    Table 14. Global Genome-Based Drug Sales by Region (2025-2030) & (Kiloton)
    Table 15. Global Genome-Based Drug Sales Market Share by Region (2019-2024)
    Table 16. Global Genome-Based Drug Sales Market Share by Region (2025-2030)
    Table 17. Global Genome-Based Drug Sales by Manufacturers (2019-2024) & (Kiloton)
    Table 18. Global Genome-Based Drug Sales Share by Manufacturers (2019-2024)
    Table 19. Global Genome-Based Drug Revenue by Manufacturers (2019-2024) & (US$ Million)
    Table 20. Global Genome-Based Drug Revenue Share by Manufacturers (2019-2024)
    Table 21. Global Key Players of Genome-Based Drug, Industry Ranking, 2022 VS 2023 VS 2024
    Table 22. Genome-Based Drug Price by Manufacturers 2019-2024 (US$/Ton)
    Table 23. Global Genome-Based Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
    Table 24. Global Genome-Based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Genome-Based Drug as of 2023)
    Table 25. Global Key Manufacturers of Genome-Based Drug, Manufacturing Base Distribution and Headquarters
    Table 26. Global Key Manufacturers of Genome-Based Drug, Product Offered and Application
    Table 27. Global Key Manufacturers of Genome-Based Drug, Date of Enter into This Industry
    Table 28. Mergers & Acquisitions, Expansion Plans
    Table 29. Global Genome-Based Drug Sales by Type (2019-2024) & (Kiloton)
    Table 30. Global Genome-Based Drug Sales by Type (2025-2030) & (Kiloton)
    Table 31. Global Genome-Based Drug Sales Share by Type (2019-2024)
    Table 32. Global Genome-Based Drug Sales Share by Type (2025-2030)
    Table 33. Global Genome-Based Drug Revenue by Type (2019-2024) & (US$ Million)
    Table 34. Global Genome-Based Drug Revenue by Type (2025-2030) & (US$ Million)
    Table 35. Global Genome-Based Drug Revenue Share by Type (2019-2024)
    Table 36. Global Genome-Based Drug Revenue Share by Type (2025-2030)
    Table 37. Genome-Based Drug Price by Type (2019-2024) & (US$/Ton)
    Table 38. Global Genome-Based Drug Price Forecast by Type (2025-2030) & (US$/Ton)
    Table 39. Global Genome-Based Drug Sales by Application (2019-2024) & (Kiloton)
    Table 40. Global Genome-Based Drug Sales by Application (2025-2030) & (Kiloton)
    Table 41. Global Genome-Based Drug Sales Share by Application (2019-2024)
    Table 42. Global Genome-Based Drug Sales Share by Application (2025-2030)
    Table 43. Global Genome-Based Drug Revenue by Application (2019-2024) & (US$ Million)
    Table 44. Global Genome-Based Drug Revenue by Application (2025-2030) & (US$ Million)
    Table 45. Global Genome-Based Drug Revenue Share by Application (2019-2024)
    Table 46. Global Genome-Based Drug Revenue Share by Application (2025-2030)
    Table 47. Genome-Based Drug Price by Application (2019-2024) & (US$/Ton)
    Table 48. Global Genome-Based Drug Price Forecast by Application (2025-2030) & (US$/Ton)
    Table 49. US & Canada Genome-Based Drug Sales by Type (2019-2024) & (Kiloton)
    Table 50. US & Canada Genome-Based Drug Sales by Type (2025-2030) & (Kiloton)
    Table 51. US & Canada Genome-Based Drug Revenue by Type (2019-2024) & (US$ Million)
    Table 52. US & Canada Genome-Based Drug Revenue by Type (2025-2030) & (US$ Million)
    Table 53. US & Canada Genome-Based Drug Sales by Application (2019-2024) & (Kiloton)
    Table 54. US & Canada Genome-Based Drug Sales by Application (2025-2030) & (Kiloton)
    Table 55. US & Canada Genome-Based Drug Revenue by Application (2019-2024) & (US$ Million)
    Table 56. US & Canada Genome-Based Drug Revenue by Application (2025-2030) & (US$ Million)
    Table 57. US & Canada Genome-Based Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 58. US & Canada Genome-Based Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 59. US & Canada Genome-Based Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 60. US & Canada Genome-Based Drug Sales by Country (2019-2024) & (Kiloton)
    Table 61. US & Canada Genome-Based Drug Sales by Country (2025-2030) & (Kiloton)
    Table 62. Europe Genome-Based Drug Sales by Type (2019-2024) & (Kiloton)
    Table 63. Europe Genome-Based Drug Sales by Type (2025-2030) & (Kiloton)
    Table 64. Europe Genome-Based Drug Revenue by Type (2019-2024) & (US$ Million)
    Table 65. Europe Genome-Based Drug Revenue by Type (2025-2030) & (US$ Million)
    Table 66. Europe Genome-Based Drug Sales by Application (2019-2024) & (Kiloton)
    Table 67. Europe Genome-Based Drug Sales by Application (2025-2030) & (Kiloton)
    Table 68. Europe Genome-Based Drug Revenue by Application (2019-2024) & (US$ Million)
    Table 69. Europe Genome-Based Drug Revenue by Application (2025-2030) & (US$ Million)
    Table 70. Europe Genome-Based Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 71. Europe Genome-Based Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 72. Europe Genome-Based Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 73. Europe Genome-Based Drug Sales by Country (2019-2024) & (Kiloton)
    Table 74. Europe Genome-Based Drug Sales by Country (2025-2030) & (Kiloton)
    Table 75. China Genome-Based Drug Sales by Type (2019-2024) & (Kiloton)
    Table 76. China Genome-Based Drug Sales by Type (2025-2030) & (Kiloton)
    Table 77. China Genome-Based Drug Revenue by Type (2019-2024) & (US$ Million)
    Table 78. China Genome-Based Drug Revenue by Type (2025-2030) & (US$ Million)
    Table 79. China Genome-Based Drug Sales by Application (2019-2024) & (Kiloton)
    Table 80. China Genome-Based Drug Sales by Application (2025-2030) & (Kiloton)
    Table 81. China Genome-Based Drug Revenue by Application (2019-2024) & (US$ Million)
    Table 82. China Genome-Based Drug Revenue by Application (2025-2030) & (US$ Million)
    Table 83. Asia Genome-Based Drug Sales by Type (2019-2024) & (Kiloton)
    Table 84. Asia Genome-Based Drug Sales by Type (2025-2030) & (Kiloton)
    Table 85. Asia Genome-Based Drug Revenue by Type (2019-2024) & (US$ Million)
    Table 86. Asia Genome-Based Drug Revenue by Type (2025-2030) & (US$ Million)
    Table 87. Asia Genome-Based Drug Sales by Application (2019-2024) & (Kiloton)
    Table 88. Asia Genome-Based Drug Sales by Application (2025-2030) & (Kiloton)
    Table 89. Asia Genome-Based Drug Revenue by Application (2019-2024) & (US$ Million)
    Table 90. Asia Genome-Based Drug Revenue by Application (2025-2030) & (US$ Million)
    Table 91. Asia Genome-Based Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 92. Asia Genome-Based Drug Revenue by Region (2019-2024) & (US$ Million)
    Table 93. Asia Genome-Based Drug Revenue by Region (2025-2030) & (US$ Million)
    Table 94. Asia Genome-Based Drug Sales by Region (2019-2024) & (Kiloton)
    Table 95. Asia Genome-Based Drug Sales by Region (2025-2030) & (Kiloton)
    Table 96. Middle East, Africa and Latin America Genome-Based Drug Sales by Type (2019-2024) & (Kiloton)
    Table 97. Middle East, Africa and Latin America Genome-Based Drug Sales by Type (2025-2030) & (Kiloton)
    Table 98. Middle East, Africa and Latin America Genome-Based Drug Revenue by Type (2019-2024) & (US$ Million)
    Table 99. Middle East, Africa and Latin America Genome-Based Drug Revenue by Type (2025-2030) & (US$ Million)
    Table 100. Middle East, Africa and Latin America Genome-Based Drug Sales by Application (2019-2024) & (Kiloton)
    Table 101. Middle East, Africa and Latin America Genome-Based Drug Sales by Application (2025-2030) & (Kiloton)
    Table 102. Middle East, Africa and Latin America Genome-Based Drug Revenue by Application (2019-2024) & (US$ Million)
    Table 103. Middle East, Africa and Latin America Genome-Based Drug Revenue by Application (2025-2030) & (US$ Million)
    Table 104. Middle East, Africa and Latin America Genome-Based Drug Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)
    Table 105. Middle East, Africa and Latin America Genome-Based Drug Revenue by Country (2019-2024) & (US$ Million)
    Table 106. Middle East, Africa and Latin America Genome-Based Drug Revenue by Country (2025-2030) & (US$ Million)
    Table 107. Middle East, Africa and Latin America Genome-Based Drug Sales by Country (2019-2024) & (Kiloton)
    Table 108. Middle East, Africa and Latin America Genome-Based Drug Sales by Country (2025-2030) & (Kiloton)
    Table 109. Sandoz International Company Information
    Table 110. Sandoz International Description and Major Businesses
    Table 111. Sandoz International Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 112. Sandoz International Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 113. Sandoz International Recent Developments
    Table 114. Teva pharmaceutical industries Company Information
    Table 115. Teva pharmaceutical industries Description and Major Businesses
    Table 116. Teva pharmaceutical industries Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 117. Teva pharmaceutical industries Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 118. Teva pharmaceutical industries Recent Developments
    Table 119. Mylan Company Information
    Table 120. Mylan Description and Major Businesses
    Table 121. Mylan Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 122. Mylan Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 123. Mylan Recent Developments
    Table 124. 3SBio Company Information
    Table 125. 3SBio Description and Major Businesses
    Table 126. 3SBio Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 127. 3SBio Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 128. 3SBio Recent Developments
    Table 129. Shanghai Fosun Pharmaceutical Company Information
    Table 130. Shanghai Fosun Pharmaceutical Description and Major Businesses
    Table 131. Shanghai Fosun Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 132. Shanghai Fosun Pharmaceutical Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 133. Shanghai Fosun Pharmaceutical Recent Developments
    Table 134. Tonghua Dongbao Pharmaceutical Company Information
    Table 135. Tonghua Dongbao Pharmaceutical Description and Major Businesses
    Table 136. Tonghua Dongbao Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 137. Tonghua Dongbao Pharmaceutical Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 138. Tonghua Dongbao Pharmaceutical Recent Developments
    Table 139. Biocon Company Information
    Table 140. Biocon Description and Major Businesses
    Table 141. Biocon Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 142. Biocon Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 143. Biocon Recent Developments
    Table 144. Reliance Life Sciences Company Information
    Table 145. Reliance Life Sciences Description and Major Businesses
    Table 146. Reliance Life Sciences Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 147. Reliance Life Sciences Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 148. Reliance Life Sciences Recent Developments
    Table 149. Probiomed Company Information
    Table 150. Probiomed Description and Major Businesses
    Table 151. Probiomed Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 152. Probiomed Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 153. Probiomed Recent Developments
    Table 154. Biosidus Company Information
    Table 155. Biosidus Description and Major Businesses
    Table 156. Biosidus Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 157. Biosidus Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 158. Biosidus Recent Developments
    Table 159. AMEGA Biotech Company Information
    Table 160. AMEGA Biotech Description and Major Businesses
    Table 161. AMEGA Biotech Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 162. AMEGA Biotech Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 163. AMEGA Biotech Recent Developments
    Table 164. Celltrion Company Information
    Table 165. Celltrion Description and Major Businesses
    Table 166. Celltrion Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 167. Celltrion Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 168. Celltrion Recent Developments
    Table 169. LG Life Science Company Information
    Table 170. LG Life Science Description and Major Businesses
    Table 171. LG Life Science Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 172. LG Life Science Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 173. LG Life Science Recent Developments
    Table 174. Dong-A Pharmaceutical Company Information
    Table 175. Dong-A Pharmaceutical Description and Major Businesses
    Table 176. Dong-A Pharmaceutical Genome-Based Drug Sales (Kiloton), Revenue (US$ Million), Price (US$/Ton) and Gross Margin (2019-2024)
    Table 177. Dong-A Pharmaceutical Genome-Based Drug Product Model Numbers, Pictures, Descriptions and Specifications
    Table 178. Dong-A Pharmaceutical Recent Developments
    Table 179. Key Raw Materials Lists
    Table 180. Raw Materials Key Suppliers Lists
    Table 181. Genome-Based Drug Distributors List
    Table 182. Genome-Based Drug Customers List
    Table 183. Genome-Based Drug Market Trends
    Table 184. Genome-Based Drug Market Drivers
    Table 185. Genome-Based Drug Market Challenges
    Table 186. Genome-Based Drug Market Restraints
    Table 187. Research Programs/Design for This Report
    Table 188. Key Data Information from Secondary Sources
    Table 189. Key Data Information from Primary Sources
List of Figures
    Figure 1. Genome-Based Drug Product Picture
    Figure 2. Global Genome-Based Drug Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Genome-Based Drug Market Share by Type in 2023 & 2030
    Figure 4. Insulin Product Picture
    Figure 5. Growth Hormone Product Picture
    Figure 6. Monoclonal Antibody Product Picture
    Figure 7. Other Product Picture
    Figure 8. Global Genome-Based Drug Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 9. Global Genome-Based Drug Market Share by Application in 2023 & 2030
    Figure 10. Hospital
    Figure 11. Pharmaceutical Factory
    Figure 12. Other
    Figure 13. Genome-Based Drug Report Years Considered
    Figure 14. Global Genome-Based Drug Revenue, (US$ Million), 2019 VS 2023 VS 2030
    Figure 15. Global Genome-Based Drug Revenue 2019-2030 (US$ Million)
    Figure 16. Global Genome-Based Drug Revenue Market Share by Region in Percentage: 2023 Versus 2030
    Figure 17. Global Genome-Based Drug Revenue Market Share by Region (2019-2030)
    Figure 18. Global Genome-Based Drug Sales 2019-2030 ((Kiloton)
    Figure 19. Global Genome-Based Drug Sales Market Share by Region (2019-2030)
    Figure 20. US & Canada Genome-Based Drug Sales YoY (2019-2030) & (Kiloton)
    Figure 21. US & Canada Genome-Based Drug Revenue YoY (2019-2030) & (US$ Million)
    Figure 22. Europe Genome-Based Drug Sales YoY (2019-2030) & (Kiloton)
    Figure 23. Europe Genome-Based Drug Revenue YoY (2019-2030) & (US$ Million)
    Figure 24. China Genome-Based Drug Sales YoY (2019-2030) & (Kiloton)
    Figure 25. China Genome-Based Drug Revenue YoY (2019-2030) & (US$ Million)
    Figure 26. Asia (excluding China) Genome-Based Drug Sales YoY (2019-2030) & (Kiloton)
    Figure 27. Asia (excluding China) Genome-Based Drug Revenue YoY (2019-2030) & (US$ Million)
    Figure 28. Middle East, Africa and Latin America Genome-Based Drug Sales YoY (2019-2030) & (Kiloton)
    Figure 29. Middle East, Africa and Latin America Genome-Based Drug Revenue YoY (2019-2030) & (US$ Million)
    Figure 30. The Genome-Based Drug Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023
    Figure 31. The Top 5 and 10 Largest Manufacturers of Genome-Based Drug in the World: Market Share by Genome-Based Drug Revenue in 2023
    Figure 32. Global Genome-Based Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 33. Global Genome-Based Drug Sales Market Share by Type (2019-2030)
    Figure 34. Global Genome-Based Drug Revenue Market Share by Type (2019-2030)
    Figure 35. Global Genome-Based Drug Sales Market Share by Application (2019-2030)
    Figure 36. Global Genome-Based Drug Revenue Market Share by Application (2019-2030)
    Figure 37. US & Canada Genome-Based Drug Sales Market Share by Type (2019-2030)
    Figure 38. US & Canada Genome-Based Drug Revenue Market Share by Type (2019-2030)
    Figure 39. US & Canada Genome-Based Drug Sales Market Share by Application (2019-2030)
    Figure 40. US & Canada Genome-Based Drug Revenue Market Share by Application (2019-2030)
    Figure 41. US & Canada Genome-Based Drug Revenue Share by Country (2019-2030)
    Figure 42. US & Canada Genome-Based Drug Sales Share by Country (2019-2030)
    Figure 43. U.S. Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 44. Canada Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 45. Europe Genome-Based Drug Sales Market Share by Type (2019-2030)
    Figure 46. Europe Genome-Based Drug Revenue Market Share by Type (2019-2030)
    Figure 47. Europe Genome-Based Drug Sales Market Share by Application (2019-2030)
    Figure 48. Europe Genome-Based Drug Revenue Market Share by Application (2019-2030)
    Figure 49. Europe Genome-Based Drug Revenue Share by Country (2019-2030)
    Figure 50. Europe Genome-Based Drug Sales Share by Country (2019-2030)
    Figure 51. Germany Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 52. France Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 53. U.K. Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 54. Italy Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 55. Russia Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 56. China Genome-Based Drug Sales Market Share by Type (2019-2030)
    Figure 57. China Genome-Based Drug Revenue Market Share by Type (2019-2030)
    Figure 58. China Genome-Based Drug Sales Market Share by Application (2019-2030)
    Figure 59. China Genome-Based Drug Revenue Market Share by Application (2019-2030)
    Figure 60. Asia Genome-Based Drug Sales Market Share by Type (2019-2030)
    Figure 61. Asia Genome-Based Drug Revenue Market Share by Type (2019-2030)
    Figure 62. Asia Genome-Based Drug Sales Market Share by Application (2019-2030)
    Figure 63. Asia Genome-Based Drug Revenue Market Share by Application (2019-2030)
    Figure 64. Asia Genome-Based Drug Revenue Share by Region (2019-2030)
    Figure 65. Asia Genome-Based Drug Sales Share by Region (2019-2030)
    Figure 66. Japan Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 67. South Korea Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 68. China Taiwan Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 69. Southeast Asia Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 70. India Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 71. Middle East, Africa and Latin America Genome-Based Drug Sales Market Share by Type (2019-2030)
    Figure 72. Middle East, Africa and Latin America Genome-Based Drug Revenue Market Share by Type (2019-2030)
    Figure 73. Middle East, Africa and Latin America Genome-Based Drug Sales Market Share by Application (2019-2030)
    Figure 74. Middle East, Africa and Latin America Genome-Based Drug Revenue Market Share by Application (2019-2030)
    Figure 75. Middle East, Africa and Latin America Genome-Based Drug Revenue Share by Country (2019-2030)
    Figure 76. Middle East, Africa and Latin America Genome-Based Drug Sales Share by Country (2019-2030)
    Figure 77. Brazil Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 78. Mexico Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 79. Turkey Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 80. Israel Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 81. GCC Countries Genome-Based Drug Revenue (2019-2030) & (US$ Million)
    Figure 82. Genome-Based Drug Value Chain
    Figure 83. Genome-Based Drug Production Process
    Figure 84. Channels of Distribution
    Figure 85. Distributors Profiles
    Figure 86. Bottom-up and Top-down Approaches for This Report
    Figure 87. Data Triangulation
    Figure 88. Key Executives Interviewed